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Abstract
Introduction Cervical cancer is among the most common
cancers in women worldwide. Discovery of biomarkers for
the early detection of cervical cancer would improve current
screening practices and reduce the burden of disease.
Objective In this study, we report characterization of the
human cervical mucous proteome as the first step towards
protein biomarker discovery.
Methods The protein composition was characterized using
one- and two-dimensional gel electrophoresis, and liquid
chromatography coupled with mass spectrometry. We chose
to use this combination of traditional biochemical techniques
and proteomics to allow a more comprehensive analysis.
Results and Conclusion A total of 107 unique proteins
were identified, with plasma proteins being most abundant.
These proteins represented the major functional categories
of metabolism, immune response, and cellular transport.
Removal of high molecular weight abundant proteins by
immunoaffinity purification did not significantly increase the
number of protein spots resolved. We also analyzed phos-
phorylated and glycosylated proteins by fluorescent post-
stainingprocedures.The profilingofcervicalmucousproteins
and their post-translational modifications can be used to
further our understanding of the cervical mucous proteome.
Keywords Cervical mucous.Cervical cancer biomarkers.
Mass spectrometry.2-D electrophoresis.LC/MS/MS
Introduction
Advances in proteomic technologies have greatly accelerated
the field of protein biomarker discovery. High-throughput
technologies like surface-enhanced laser desorption and
ionization-time of flight mass spectrometry (SELDI-TOF
MS) or the combination of one- or two-dimensional gel
electrophoresis (1-DE, 2-DE) methods with multidimensional
chromatographic separation and MS provide a snapshotof the
proteome. Validated protein biomarkers could be useful in
early detection of disease, monitoring disease progression or
monitoring response to treatment. Several studies have thus
focused on biomarker discovery in body fluids which would
be advantageous for eventual clinical implementation.
Cervical mucous is potentially an ideal sample to screen
for biomarkers for early detection of cervical cancer. As
cervical mucous is produced in the microenvironment
where cervical neoplasia arises, it is likely to include
proteins produced by the lesion as well as by the host in
response to the lesion.
Cervical mucous is a complex mixture of proteins
consisting of an aqueous and glycoprotein phase [1], but
is thought to have a restricted protein profile compared to
other body fluids like serum or plasma. It is recognized that
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DOI 10.1007/s12014-010-9042-3the cervix is hormonally responsive and differences in
protein composition and concentration due to menopause,
menstrual cycle, and hormonal contraceptives will impact
sample to sample comparison. CVF includes, in addition to
cervical mucous, contributions from vulvar secretions,
vaginal wall transudate, exfoliated cells, endometrial and
oviductal fluids, and metabolic products of vaginal micro-
flora [2]. Thus, proteomic characterization of CVF is suited
for exploring markers of genital tract infections or pregnancy
status or overall evaluation of reproductive tract. However,
protein contributions from multiple sites could significantly
dilute the cervical contribution that would be most represen-
tative of cervical neoplasia localized to the cervix.
To date, there have been six studies of CVF [3–8], four
of these were restricted to pregnant women [3–6]. These
studies identified from 15 to 685 proteins using gel
separation/MALDI-TOF MS ([4, 8]; 15 and 59 proteins
respectively), LC-MS/MS ([5]; 39 proteins), gel separation
and LC-MS/MS ([7]; 685 proteins), and gel separation and
LC-LC-MS/MS ([3, 6]; 150 and 205 proteins respectively).
Consistently, many CVF proteins were noted to be of
plasma origin, suggesting CVF could largely be plasma
transudate. Other major functional categories were repre-
sented by immune response, metabolism, and cellular
transport. Only one study examined cervical mucous [9],
and it focused on samples from normal women obtained
during various points of the menstrual cycle. Using gel
separation/LC-MS/MS they identified 194 proteins and
again identified plasma proteins. Cervical mucous and
CVF would be expected to share similarities in their
proteome, but for reasons stated above, the cervical mucous
is expected be more representative of cervical disease and
the local host response to cervical disease.
In our study, the cervical mucous proteome was
characterized by 2-DE and gel-based liquid chromatogra-
phy–mass spectrometry (GeLC-MS/MS) techniques. Of the
current proteomic tools, no single method can resolve an
entire proteome. Combination of several pre-fractionation
methods like gel separation and LC prior to mass
spectrometry allowed for visualization of the proteins as
well as the identification of proteins that could otherwise be
missed by a single method [10]. Also, characterization of
sub-proteomes like the glycoproteome or phosphoproteome
and immunoaffinity depletion of high abundant proteins
was attempted in order to reduce complexity and facilitate
better resolution of proteins in cervical mucous.
Materials and Methods
Sample Collection and Processing Women attending urban
colposcopy clinics were enrolled as part of an ongoing study
of cervical neoplasia [11]. Cervical mucous samples were
collected at the time of colposcopy by absorption into two
Weck-Cel® sponges (Xomed Surgical Products, Jacksonville,
FL) placed, one at a time, into the cervical os. Samples were
stored at −80°C until use. We processed 40 Weck-Cel®
sponges (one or two sponges per subject depending on
availability) with no visual blood contamination from 25
subjects who were randomly selected. The median age of the
women in this subset was 27 years (range 18–57); 90% were
black; 52% currently used hormonal contraceptive (oral,
depo-provera, or both); 62% were HPV positive and 52%
had pre-invasive cervical disease. No data was available on
the menstrual cycle at the time of sample collection.
Total protein was extracted using M-PER® extraction
reagent (M-PER, 0.15 M NaCl) (Pierce Biotechnology,
Inc., Rockford, IL) as previously established [12]. All
samples were combined and the pooled sample was
aliquoted for storage at −80°C. A pooled sample was used
in order to have sufficient volume that would allow for
optimization of the 2-DE and GeLC-MS/MS methods
described below. Total protein content was measured using
the Coomasie Plus
TM kit (Pierce Biotechnology Inc.) as per
the manufacturer’s protocol.
Depletion of Albumin and IgG Immunodepletion of the
pooled mucous sample was carried out using IgY-C12 spin
column (GenWay Biotech. Inc., San Diego, CA) following
manufacturer’s protocol. In brief, an aliquot of protein
extract (∼200 µg) was first mixed with 1× Tris-buffered saline
(TBS, 10 mM Tris, 150 mM NaCl, pH 7.4) at 1:1 ratio. The
mixture was added to IgY-C12 spin column and incubated at
room temperature with shaking for 20 min. The unbound
proteins were eluted and the column washed three times with
1× TBS buffer. The eluates from all the above steps were
combined and dried down using a lyophilizer.
Two-Dimensional Gel Electrophoresis For each gel, 80 µg
of protein extract was prepared with the 2-D Clean Up Kit
(GE Healthcare) to remove interfering components. All
reagents were purchased from Sigma-Aldrich (St. Louis,
MO) unless otherwise specified. The samples (with or
without depletion) were mixed in a rehydration buffer (7 M
u r e a ,2Mt h i o u r e a ,2 %C H A P S ,5 0m MD T T ,1 %
Pharmalyte) and incubated for 12 h followed by focusing
on an 11-cm immobilized pH gradient (IPG) strip (pH 3-11
NL, GE Healthcare) in a PROTEAN IEF cell (Bio-Rad,
Hercules, CA). Focusing was performed under the condi-
tion: 500 V constant for 500 V h; linear gradient to 1,000 V
for 800 V h; gradient to 6,000 V for 7,000 V h; gradient to
6,000 V for 3,700 V h. After the first-dimensional
isoelectric focusing, IPG strips containing proteins were
treated for 15 min with gentle shaking in the equilibration
buffer (6 M urea, 30% glycerol, 2% SDS, 50 mM Tris, pH
8.8) containing 2.5% tributyl phosphine (TBP) for protein
Clin Proteom (2010) 6:18–28 19reduction followed by protein alkylation with 3% iodoace-
tamide (IAA) to replace TBP in the buffer for another
15 min. The second-dimensional SDS-PAGE was run on an
8–16% linear gradient criterion Tris–HCl gel (Bio-rad) at
110 V for 2 h. The gels were stained with colloidal
Coomassie or SYPRO Ruby (Invitrogen, Carlsbad, CA)
dyes as per the manufacturer’s protocol.
One-Dimensional Gel Electrophoresis The sample (80 µg)
was treated with the 2-D Clean Up kit as described above.
The precipitate was solubilized in lysis buffer (1 M Tris–
HCl, 8 M urea, and 4% CHAPS, pH 8.5) and run on an 8–
16% linear gradient criterion Tris–HCl gel at 110 V for 1 h.
After colloidal Coomassie staining, the entire lane was
sliced into 40 pieces of equal size for further analysis.
Gel Staining The 2-DE gel for the characterization of post-
translational modifications on human cervical mucous pro-
teins was stained using three different dyes: Pro-Q Diamond
for phosphoproteins, Pro-Q Emerald 488 for glycoproteins,
and SYPRO Ruby for total proteins (Invitrogen) following
manufacturer’s protocol. In brief, the gels were fixed
overnight at room temperature in 500 ml fixation solution
(50% methanol, 10% acetic acid), followed by two 10-min
washsteps with ultrapure water withgentleagitation.Staining
was performed with 500 ml Pro-Q Diamond with gentle
agitation in the dark for 90 min. The gel was destained by
washing twice with 500 ml destain solution (20% acetonitrile,
50 mM sodium acetate, pH 4.0) with gentle agitation. The gel
imageswere acquiredonTyphoon9400(GEHealthcare)with
532 nm excitation and 560 nm long pass emission. After
image scanning, gels were washed two times in 3% glacial
acetic acid for 20 min each and then incubated in oxidizing
solution (1% periodic acid in 3% acetic acid) for 1 h. The
oxidizing solution was removed by washing three times with
3% glacial acetic acid for 20 min each. The gels were then
incubatedinfreshPro-QEmerald488stainingsolutionfor3h
in the dark. Destaining was done by washing the gel twice in
3% acetic acid at room temperature for 30 min each. Gel
images were acquired by Typhoon 9400 at 510 nm excitation
and 520 nm emission wavelengths. Finally, the gels were
visualized by colloidal Coomassie staining and the gel spots
of interest were excised for further characterization.
In-Gel Trypsin Digestion Sample in-gel digestion and
micro-purification were carried out on a ZipPlate micro-
SPE according to manufacturer’s In-Gel Digestion Protocol
(Millipore, Billerica,MA) withminor modifications. Briefly,
gel spots or bands were destained in buffer 1 (25 mM
ammonium bicarbonate and 5% acetonitrile) for 30 min and
then in buffer 2 (25 mM ammonium bicarbonate and 50%
acetonitrile) for an additional 30 min. Following reduction
with 10 mM dithiothreitol and alkylation with 55 mM IAA,
the gel pieces were incubated in 15 or 30 µL of trypsin
(165 ng) solution and incubated overnight at 37°C. The
peptides were extracted, micro-purified, vacuum-dried and
resuspended in 1% formic acid and 2% acetonitrile for mass
spectrometric analysis.
Mass Spectrometry and Database Analysis Nanocapillary
LC-MS/MS analysis was performed in a Micromass Q-Tof
Ultima mass spectrometer equipped with a nanospray ion
source and coupled with an nanoAcquity ultraperformance
liquid chromatography system (UPLC; Waters, Milford, MA).
The protein digest (2 µl) was loaded onto an in-house packed
reverse phase C18 capillary column (∼15 cm, 75 µm inner
diameter) and separated using a linear gradient of 15% to 45%
of buffer B (acetonitrile, 0.1% formic acid) in buffer A (water,
0.1% formic acid) in 60 min (2-DE gel samples) or 80 min
(1-DE gel samples) at a flow rate of 0.5 µl/min.
All mass spectra were obtained in the positive-ion mode.
An electric potential of 3.5 kV was applied to the emitter in
the ion source. The acquisition of data was performed on a
MassLynx data system (version 4.0; Waters) using a data-
dependent mode where the four most intense precursors in
a survey scan were isolated for collision-induced dissoci-
ation. Resulting MS/MS data were searched for protein
candidates with automated database searching against
NCBI nr database using MASCOT Daemon software
(Matrix Sciences, Boston, MA). The peptide mass
tolerance was set to ±50 ppm, and fragment mass tolerance
was set to ±0.3 Da. Carboxyamidomethyl cysteine and
oxidized methionine were set as variable modifications. All
peptides identified with score less than 50 and one matched
peptide during MASCOTsearches were examined by manual
inspection. Functional categories were annotated by literature
surveys in PubMed or based on classification from the
Database for Annotation, Visualization and Integrated
Discovery (DAVID) [13].
Results and Discussion
Identification of Cervical Mucous Proteins by Proteomic
Techniques Complex protein mixtures can be resolved
effectively according to their isoelectric points and molecular
weights by 2-DE. While gel-based approaches provide good
separation and direct visualization of individual proteins,
highly accurate LC-MS/MS analysis on protein digests
extracted from gel spots leads to high-confidence identifica-
tionofthese proteins.Therefore,the combination ofthese two
techniques becomes a powerful tool in characterizing a
proteome. The proteins extracted from pooled cervical
mucous samples were first separated by 2-DE method
(Fig. 1a). 183 spots were excised and subjected to in-gel
trypsin digestion followed by liquid chromatography coupled
20 Clin Proteom (2010) 6:18–28to mass spectrometric analysis. High-confidence protein
identification was accomplished by searching non-
redundant protein databases with tandem mass spectra of
the peptide mixtures. A total of 134 protein spots were
successfully identified that represented 79 unique proteins
(Table 1). Several spots resulted in identical protein
identification, presumably due to the formation of protein
isoforms bearing various modified residues introduced by
post-translational modification or during sample processing.
Applying different sample preparation and fractionation
methods to a single sample could increase the total number of
unique proteins identified. To get a broader proteome
coverage, we analyzed the protein composition using two
other techniques; 2-DE after immunoaffinity-based depletion
ofhighlyabundantproteins,and the combinationof1-DEand
liquid chromatography coupled mass spectrometry (GeLC-
MS/MS). Removal of highly abundant proteins in serum or
other body fluid samples can effectively improve the number
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Fig. 1 Gel electrophoresis of the proteins extracted from cervical mucous. a 2-DE gel image (Coomassie staining); b 2-DE gel after depletion
(SYPRO Ruby staining); and c 1-DE gel image (Coomassie staining). Only spots representing identified proteins are labeled on gel images
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Protein name Acc. no.
a MW
(kDa)
pI MASCOT score Matched
peptides
Sequence
coverage (%)
Method
b Spot no.
c
14-3-3 protein epsilon P62258 29.1 4.63 92 3 10 T 51
14-3-3 protein sigma P31947 27.7 4.68 71 3 10 T 51
14-3-3 protein zeta/delta P63104 27.7 4.73 181 5 25 T 50
6-phosphogluconate
dehydrogenase
P52209 53.1 6.80 51 2 5 T,G 46
Alcohol dehydrogenase
[NADP+]
d
P14550 36.5 6.32 75 2 6 T 122
Alpha-1-acid glycoprotein
1 precursor
e
P02763 23.4 4.93 194 6 34 T,G 56
Alpha-1-antichymotrypsin
precursor
e
P01011 47.6 5.33 285 7 21 T 98–100
Alpha-1-antitrypsin precursor
e P01009 46.7 5.37 1092 16 48 T,G, D 45, 57, 59, 97, 123, d19
Alpha-enolase P06733 47.1 7.01 338 9 19 T,G 46–47, 80
Annexin A1 P04083 38.7 6.57 1893 12 43 T,G, D 35–36, 85, 124,
d78–82, d91
Annexin A2 P07355 38.5 7.57 573 13 43 T,G, D 82, 111–112, d37,
d45–47, d73, d85
Annexin A3 P12429 36.4 5.63 758 12 42 T,G, D 32–33, 84, d88, d96
Annexin A5 P08758 35.9 4.94 167 7 25 T,G 31
Antileukoproteinase 1 precursor P03973 14.3 9.11 54 2 6 G
Anterior gradient protein 2
homolog precursor
O95994 19.9 9.03 126 4 26 T,G 118–119
Apolipoprotein A-I precursor
e P02647 30.8 5.56 1464 16 56 T,G 30, 49, 106–109
Arginase-1 P05089 34.7 6.72 36 3 10 T 125
ATP synthase subunit beta P06576 56.5 5.26 64 2 4 D d51
Beta-actin
e P60709 41.7 5.29 926 10 34 T,G 58, 96
Calregulin
d P27797 48.1 4.29 92 3 8 T, D 101, d48
Carbonic anhydrase 1 P00915 28.9 6.59 133 5 22 T, D 34, 53, 54, d72
Catalase P04040 59.7 6.9 38 1 1 D d13
Cathelicidin antimicrobial
peptide precursor
d
P49913 19.3 9.48 135 2 10 T, G 119–120
Ceruloplasmin precursor P00450 122.1 5.44 124 4 4 T,G, D 69, d53
Complement C3 precursor 1637 187.0 6.02 254 15 11 T,G, D 34, 43, d5, d7
Complement C4-A precursor 1618 192.7 6.65 60 2 1 D d38
Complement factor B precursor P00751 85.5 6.67 57 4 5 G
Cystatin-A P01040 11.0 5.38 126 2 30 T,G 21, 24
Cystatin-B P04080 11.1 6.96 85 2 24 G
Elongation factor 1-alpha 1 P68104 50.1 9.10 70 3 6 T 87
Endoplasmin precursor P14625 92.4 4.76 168 6 8 T, D 62, d50
F-actin-capping protein
subunit alpha-1
P52907 32.9 5.45 43 1 3 T 32
Fatty-acid-binding
protein, epidermal
Q01469 15.2 6.60 315 6 40 T,G 10
Flavin reductase
d P30043 22.1 7.13 35 1 7 T 121
Fructose-bisphosphate
aldolase A
P04075 39.4 8.30 44 1 3 D d44
Glutamine synthetase
d P15104 42.0 6.43 99 5 19 G
Glutathione-S-transferase P
e P09211 23.3 5.43 73 2 13 T,G 29
Glyceraldehyde-3-phosphate
dehydrogenase
P04406 36.0 8.57 168 6 25 T,G 37, 48
Haptoglobin precursor P00738 45.2 6.13 226 5 14 T,G 72
Heat-shock 70 kDa protein 1 P08107 69.9 5.48 311 11 17 T, D 126, d19
Heat-shock 70 kDa protein 1 L
d P34931 70.3 5.76 153 7 10 T 126
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Protein name Acc. no.
a MW
(kDa)
pI MASCOT score Matched
peptides
Sequence
coverage (%)
Method
b Spot no.
c
Heat-shock 70 kDa protein 5 P11021 72.3 5.07 261 10 20 T 64
Heat-shock 70 kDa protein 6
d P17066 70.9 5.81 125 6 7 T 126
Heat-shock 70 kDa protein 8 P11142 70.9 5.37 240 7 16 T, D 79, 126, d22
Heat-shock protein beta-1 P04792 22.8 5.98 51 1 4 G
Heat-shock protein HSP 90-alpha P07900 84.6 4.94 354 10 16 T 63
Heat-shock protein HSP 90-beta P08238 83.2 4.97 177 6 9 T 63
Hemoglobin subunit alpha P69905 15.2 8.72 1787 7 68 G, D 1–3, 13, 22, 78, d81
Hemoglobin subunit beta P68871 16.0 6.75 4704 12 95 T,G, D 1, 3–6, 8, 13, 34, 70, d61
Hemoglobin subunit delta P02042 16.0 7.85 2495 7 46 G
Hemopexin precursor P02790 51.6 6.55 43 2 4 T
Histone H4 P62805 11.4 11.40 40 2 17 G
Ig alpha-1 chain C region P01876 37.6 6.08 251 6 25 T,G 70
Ig gamma-1 chain C region P01857 36.0 8.46 1881 10 37 T,G 38, 66, 67, 68
Ig gamma-2 chain C region P01859 35.9 7.66 745 6 21 T,G
Ig heavy chain V-III region BRO P01766 13.2 6.45 49 1 15 G
Ig kappa chain V-I region Lay P01605 11.8 7.96 46 1 8 G
Ig kappa chain C region
e P01834 11.6 5.58 3002 5 80 T,G 28, 30, 52–55, 76, 113
Ig kappa chain V-I region OU P01606 11.8 9.94 67 3 24 G
Ig kappa chain V-II region TEW P01617 12.3 5.69 89 3 34 G
Ig kappa chain V-III region B6 P01619 11.6 9.34 64 1 16 G
Ig kappa chain V-III region SIE P01620 11.8 8.70 407 3 39 T,G 55, 76
Ig kappa chain V-III region
VG precursor (Fragment)
P04433 12.6 4.85 42 2 15 G
Ig kappa chain V-IV region
precursor (Fragment)
P06312 13.4 5.09 45 1 7 G
Ig lambda chain C regions P01842 11.2 6.92 597 5 75 G
Ig lambda chain V-I region HA P01700 11.9 9.07 39 2 18 G
IgGFc-binding protein precursor 4878 571.6 5.12 455 18 4 T,G 102, 127
ITI heavy chain H4 Q14624 103.3 6.51 29 2 2 D d53
Isocitrate dehydrogenase [NAD]
subunit alpha
d
P50213 39.6 6.47 51 1 2 T
Lactoferrin P02788 78.1 8.50 110 5 8 T,G, D 74, d3
Lysozyme C precursor P61626 16.5 9.38 335 4 24 T,G 28, 70, 77
Myeloblastin precursor P24158 27.8 8.72 136 6 11 T,G, D 86, d21
Neutrophil defensin 1 precursor P59665 10.2 5.71 471 3 26 G
Neutrophil gelatinase-associated
lipocalin precursor
P80188 22.5 9.02 494 5 32 T,G 75, 91, 92
Peptidyl-prolyl cis–trans
isomerase A
P62937 18.0 7.68 132 4 28 T,G, D 116, 117, d70
Peroxiredoxin-1 Q06830 22.1 8.27 52 1 5 D d62
Peroxiredoxin-5 P30044 22.0 8.85 57 3 18 T 128
PH domain leucine-rich repeat
protein phosphatase
d
O60346 185 5.88 43 2 43 G
Phosphoglycerate kinase 1 P00558 44.6 8.30 190 8 26 T,G 38, 110
Plastin-1
d Q14651 70.3 5.33 41 2 2 G
Plastin-2
e P13796 70.2 5.20 345 14 13 T,G 65
Poly-Ig receptor
e P01833 83.2 5.58 451 7 11 T,G 62, 63
Profilin-1 P07737 15 8.44 163 4 37 G, D d1–2
Proteasome subunit alpha type 5
d P28066 26.3 4.74 66 2 10 T 129
Protein disulfide isomerase
precursor
P07237 57.1 4.76 197 6 12 T, D 60, d14, d49
Clin Proteom (2010) 6:18–28 23of proteins identified by decreasing the dynamic range of
protein levels [14] .A ss h o w ni nF i g .1b, immunodepletion
effectively removed albumin and immunoglobulins from the
pooled mucous sample. The biggest spot corresponding to
serum albumin on the previous gel (Fig. 1a) almost disap-
peared after depletion (Fig. 1b), allowing a few more protein
spots to be resolved by 2-DE. Ninety-one gel spots were
selected and LC-MS/MS analysis of these features allowed
the identification of ten unique proteins in addition to those
identified prior to immunodepletion.
In the GeLC-MS/MS method, the sample was first
fractionated by 1-DE and the protein lane excised into 40
equally spaced gel slices (Fig. 1c). Nanocapillary LC-MS/
MS analysis of the peptides generated from in-gel digestion
of all gel bands resulted in the identification of 63 unique
proteins from 7,963 tandem mass spectra.
Overall, a total of 107 unique proteins were detected
from the combination of the three approaches (Fig. 2).
There was overlap in the proteins detected by all methods,
but each identified some unique proteins, indicating the
advantage of utilizing multiple techniques in sample
preparation, fractionation, and analysis. Similar to the
findings in CVF, the functional annotation of the majority
of identified proteins are metabolism, immune response,
and cellular transport process (Fig. 3) .B a s e do nt h e
intensities of the protein spots on the 2-DE gels and the
MASCOT scores of the proteins identified from GeLC-MS/
MS method, the major high abundant proteins were plasma
proteins including serum albumin, immunoglobulins, he-
moglobins, alpha-1-antitrypsin, and transferrin. Also abun-
dant were calcium-binding proteins S100-A8 and S100-A9.
Interestingly, 14 proteins, identified with a superscripted
letter “d” in Table 1, were not reported in previous
descriptions of CVF and cervical mucous [3–9].
While our preliminary study precludes comment on the
role of proteins detected to serve as biomarkers of cervical
Table 1 (continued)
Protein name Acc. no.
a MW
(kDa)
pI MASCOT score Matched
peptides
Sequence
coverage (%)
Method
b Spot no.
c
Protein S100-A11 P31949 11.7 6.56 48 2 8 T 13
Protein S100-A6
d P06703 10.1 5.33 50 3 46 T,G 23
Protein S100-A7 P31151 11.5 6.27 194 7 61 T,G 11
Protein S100-A8
e P05109 10.8 6.51 1083 8 50 T,G, D 6, 7, 9, 12, 27, 130, d66
Protein S100-A9
e P06702 13.2 5.71 1526 7 63 T,G 8, 15–16, 19–20, 25, 45
Protein S100-A12 P80511 10.6 41 2 D d64
Pyruvate kinase isozymes M1/M2 P14618 57.9 7.96 158 5 10 T 73
Serpin B1 P30740 42.7 5.90 707 14 43 T,G, D 42, 93, 131, d16, d26
Serpin B13 Q9UIV8 44.2 5.48 107 6 22 T, D 72, d25
Serpin B3
e P29508 44.5 6.35 2296 19 46 T,G, D 39–42, 71, 88–89, 91–92,
132–134, d17, d26–29
Serum albumin precursor P02768 69.3 5.92 15383 119 71 T,G, D 58, 71, 83, 88, d15
Small proline-rich protein 3 Q9UBC9 18.1 8.86 94 5 23 G
Superoxide dismutase [Mn] P04179 24.7 8.35 78 3 13 T 118
Thioredoxin P10599 11.7 4.82 49 1 12 G, D d60
Transaldolase P37837 37.5 6.36 154 2 6 T 90, 94–95
Transferrin
e P02787 77.0 6.81 855 20 32 T,G 61
Transthyretin precursor P02766 15.9 5.52 228 6 63 T 18, 26
Triosephosphate isomerase P60174 26.7 6.45 83 4 19 T 52
Tropomyosin-1 alpha chain
e P09493 32.6 4.69 129 3 9 T 105
Tropomyosin beta chain
e P07951 32.8 4.66 153 3 9 T 104
Ubiquitin P62988 8.6 6.56 84 2 32 T 14
Vitronectin precursor P04004 54.2 5.22 59 1 2 T 100
aSwiss-Prot protein accession number
bT 2D gel data, G GeLC-MS/MS data, D 2D-gel after depletion
cXX and dXX represent the numbers shown in Figs. 1a and 2b, respectively
dProteins not found in previously reported CVF and cervical mucous studies (Refs. [3–9])
ePTM proteins identified in this study. The region denoting heat-shock proteins and Immunoglobulins also showed glycosylation as seen in Fig. 4a
24 Clin Proteom (2010) 6:18–28disease, it is of interest that several identified proteins have
been previously linked to cervical carcinoma and, in some
cases, to pre-invasive disease. Specifically, Annexin, tropo-
myosin, 14-3-3 sigma, calreticulin and anterior gradient
protein 2 will be discussed.
Protein profiling of tissue biopsies has shown Annexin
A1, A2, and A5 to be upregulated in cancer when compared
to normal tissue [15–17]. Annexins are a family of calcium
and phospholipid binding proteins. Many members of the
Annexin family are known to undergo alternate splicing
yielding isoforms involved in cytoskeleton and cell motil-
ity. Other cytoskeletal proteins like tropomysoin 1 and 2
were reported to be downregulated in squamous cervical
carcinoma tissue [15]. Isoforms of tropomyosin 1 are
thought to prevent proper assembly of microfilaments thus
promoting malignant transformation of the cells [18].
The 14-3-3 proteins are a family of ubiquitously expressed
eukaryoticproteinsthatmodulateanarrayofcellularfunctions
including cell cycle control, metabolism, apoptosis and gene
transcription. 14-3-3 sigma has been found to be a tumor
suppressor [19]. Downregulation of 14-3-3 epsilon was
reported in squamous cell carcinoma of the cervix [15, 19].
Alterations in the levels of calreticulin protein have been
noted in several cancers, with the protein being down-
regulatedincervical cancerwhencomparedtonormalvaginal
tissue[16]. While anterior gradient protein 2 (AGR2) has not
been examined in relation to cervical cancer, it has been
associated with pancreatic cancer [20]. AGR2 is a member
of the protein disulfide isomerase family that is involved in
intestinal mucus production, which could have implications
for its presence in cervical mucous [21].
The fact that our study detected a lower number of
proteins than in some of the studies of the CVF proteome
could be attributed to the difference in the sample itself
(sample collection and extraction), the need to study pooled
rather than individual samples, and limits of our analysis
methods. In addition, the absorbent wick used to focus
collection at the cervix may not release all proteins [22]. At
the same time the focused collection restricts sampling to a
local region of the cervix where neoplastic changes occur.
In the study by Shaw et al. [7], gauze was placed in the
vagina for 1 h, a method quite different from the Weck-Cel
and one that is unlikely to be clinically useful. In addition,
the use of a pooled sample has the effect of diluting individual
differences thereby limiting detection to proteins shared in
common by several members in the pool. Both pooled and
individual CVF samples were profiled by Shaw et al. [7]; 282
proteins were identified in the individual sample as opposed
to 181 proteins in the pooled sample, with only 91 proteins
represented in both sets. Finally, the number of proteins
resolved could be expected to be increased with the use of
gel-free fractionation methods such as polysulfoethyl strong
cation exchange fractionation [3, 7, 23]a sw e l la sw i t ha
higher sensitivity mass spectrometer.
Characterization of Phosphorylation and Glycosylation of
Cervical Mucous Proteins Post-translational modification
(PTM) plays an important role in cellular events by altering
the physical and chemical property, stability, activity and
function of proteins. Among the hundreds of known PTMs,
phosphorylation and glycosylation are two of the most
common modifications that affect protein function. Aber-
rant modifications such as hyper-phosphorylation and
changes in the glycosylation patterns are usually associated
with human diseases and several cancers [24, 25]. A
multiplexedgelstaining methodhasbeenrecentlydeveloped
for the detection of these two popular PTMs together in
which 1-DE, or 2-DE gels can be sequentially stained with
glycol-specific Pro-Q Emerald, phosphor-specific Pro-Q
Diamond, and SYPRO Ruby (for total protein) fluorescent
dyes [26]. Unambiguous spot matching of phosphoproteins
and glycoproteins to the total proteins can be made by direct
comparison with the total protein profile in the same gel and
lownanogramsensitivitycanbeachieved.Incomparisonwith
other techniques such as radioisotope labeling and immuno-
detection with antibodies, the fluorescent dye staining method
provides a safe, simple, and streamlined way for highly
Unknown Signal transduction
6%
Signal transduction
1%
Immune response
Enzyme regulator
5%
26% Cell proliferation
5%
Cell differentiation
5%
5%
Cell organization
8% 8%
Transport
11%
Metabolism
33% 33%
Fig. 3 Functional annotation of proteins identified in cervical mucous
Depl 2D E - etion
7
7
30
14
28 3
18
MS/MS GeLC-
Fig. 2 Total number of proteins
identified using three different
strategies for protein
fractionation
Clin Proteom (2010) 6:18–28 25sensitive detection of protein phosphorylation and glycosyl-
ation in a complex sample [27].
Theexistenceofphospho-andglycoproteinsinthecervical
mucous proteome was implicated by prior detection of some
glycoproteins, protein kinases and phosphatases in this study
(Table 1). Identification of phosphoproteins and glycopro-
teins could provide information for understanding molecular
mechanisms of protein function and regulation in the
development of cervical cancer and for the discovery of
post-translationally modified biomarkers. Utilizing the
multiple-staining technique, we obtained 2-D gel images of
glyco- and phosphoproteins within the cervical mucous
proteome where the visualization of positive control bands
on the lane of molecular weight markers indicated the
efficient labeling of modified proteins (Fig. 4). The identities
of modified proteins were determined by comparing gel spots
on phospho-, glyco-, and total protein images with the
knowledge of prior identification, while some spots were
reanalyzed using LC-MS/MS for confirmation. As expected,
several proteins were modified by either glycosylation, or
phosphorylation, or both (Table 1;F i g .4a and b). However,it
should be noted that no individual phosphor- or glycol-
peptides were detected in the MS/MS data, presumably due to
the low quantity of PTM modified proteins. A larger amount
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Fig. 4 2-DE gel images of
cervical mucous proteins
stained for phosphoproteins and
glycoproteins. a Staining with
Pro-Q Emerald for detection of
glycosylated proteins; b Stain-
ing with Pro-Q diamond for
detection of phosphorylated
proteins. The enlarged area
(bottom left) was compared with
the corresponding region in the
total protein image stained with
SYPRO Ruby fluorescent dye
(bottom right). The relative in-
tensities of four labeled spots
representing S-100 A9 protein
are listed in parenthesis
26 Clin Proteom (2010) 6:18–28of starting material and techniques to enrich for these peptides
would be required for direct detection of modified peptides.
Acute-phase plasma proteins like α-1-antichymotrypsin
and α-1-antitrypsin, were both phosphorylated and glyco-
sylated (Fig. 4a and b). These serine protease inhibitors
have been implicated in several human diseases including
cancer, and the effect of glycosylation in different cancers is
being studied [28, 29]. Heat-shock proteins (HSP), which
serve as molecular chaperones, were another group that
were overexpressed and are generally linked to poor
prognosis in several cancers [30]. HSP 40, HSP 60, and
HSP 70 have been shown to be upregulated in pre-invasive
lesions of the cervix [31]. Mucins, which are common
glycoproteins in mucous [32], were not identified in the
present study. Since all three of our approaches include one
step of separation/fractionation in SDS/polyacrylamide gel
electrophoresis, mucins could have failed to migrate at all
into the gels, presumably due to the combination of large
size and lack of charged residues [33].
Apart from serpins, several phosphorylated proteins like
apolipoprotein A1, actin, plastin 2, glutathione-S-transfer-
ase P, and immunoglobulins were identified (Fig. 4b). Two
high-intensity spots (PS1 and PS2) on the phosphorprotein
image were identified as protein S100-A9 by unambiguous
spot matching with unphosphorylated spots (S1 and S2)o n
the total protein gel (Fig. 4b). While two separated spots
(S1 and S2) identified as one protein could be caused by
some unknown modification(s), increased mass and nega-
tive charges due to partial phosphorylation of the protein/
isoform could lead to the formation of new spots shifting to
high mass and low pI areas as indicated on the 2-DE gel
(PS1 and PS2). If this is the case, the phosphorylation level
of S100-A9 could be relatively high (>20%) based on the
ratios of the relative intensities of these spots on the total
protein 2-D gel. S100-A9 is a member of the S100 family
of calcium-binding proteins and has been demonstrated to
be a tumor suppressor in some cancers but a tumor
promoter in others [34]. Phosphorylation of S100-A9 is
thought to play a role in mediating MAPK-dependent
functional responses in human neutrophils [35]. A few
proteomic studies have also detected differential abundance
of this protein in relation to intra-amniotic inflammation,
preterm labor/birth, as well as breast and prostate cancer
[6, 36–38]. Biological meaning of the high level expression
and phosphorylation of protein S100-A9 in the cervical
mucous proteome with respect to cervical disease will be
investigated in a future study.
Conclusion and Future Work
The expression profiling of human cervical mucous proteins
was investigated by a combination of proteomic techniques
in this study. One hundred eighty-three of the 2-DE gel spots
were analyzed and 79 proteins were identified. An additional
28 proteins were identified from GeLC-MS/MS and deple-
tion experiments. Fourteen of these 107 proteins were
determined to be modified with phosphorylation and/or
glycosylation. Our data indicated that plasma proteins were
abundant in cervical mucous. The majority of proteins
identified could be categorized under metabolism and
immune-response functional groups. This study found 14
proteins not previously identified in studies of CVF or
cervical mucous. Further studies will determine the proteins
differentially expressed in disease samples and investigate
their potential as protein biomarkers for early detection of
cervical neoplasia.
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